Tobacco Investment Means E-Cigarette Growth, But Drug Path Raises Questions
This article was originally published in The Pink Sheet Daily
Stakeholders discussed electronic cigarettes at an FDA public hearing on smoking cessation, reflecting big tobacco’s buy-in to the market. Firms appear to have a choice between remaining in tobacco’s regulatory space, or following the costly, potentially unclear route to an NDA.
You may also be interested in...
CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.